Drug Combination Details
| General Information of the Combination (ID: C50185) | |||||
|---|---|---|---|---|---|
| Name | Hesperetin NP Info | + | Platinum Drug Info | ||
| Structure |
|
+ |
|
||
| Disease |
Lung cancer
[ICD-11: 2C25]
|
Investigative | [1] | ||
| Combinatorial Therapeutic Effect(s) Validated Clinically or Experimentally | ||||||
|---|---|---|---|---|---|---|
| α. Enhancing Drug Efficacy by This Combination | ||||||
| Achieving Therapeutic Synergy | Click to Show/Hide | |||||
| Experiment 1 Reporting the Effect of This Combination | [1] | |||||
| Molecule(s)
Regulation |
Down-regulation | Expression | UGT1A6 | Molecule Info |
Pathway MAP
|
|
| In-vitro Model | A-549 | CVCL_0023 | Lung adenocarcinoma | Homo sapiens | ||
| LL/2 (LLC1) | CVCL_4358 | Malignant tumors | Mus musculus | |||
| In-vivo Model | Xenograft tumors were established by subcutaneous injection of 1*106 LLC cells into 6-week-old male C57BL/6 mice. | |||||
| Experimental
Result(s) |
Hesperetin can synergize platinum drugs by inhibiting UGT1A3 and increasing levels of reactive oxygen species (ROS). | |||||
| References | ||||
|---|---|---|---|---|
| Reference 1 | Combination of hesperetin and platinum enhances anticancer effect on lung adenocarcinoma. Biomed Pharmacother. 2019 May;113:108779. | |||
